N-butyl-N'-<(ethoxycarbonyl)methyl>urea | 29346-50-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-butyl-N'-<(ethoxycarbonyl)methyl>urea
• 英文别名: N'-Butyl-N-aethoxycarbonylmethyl-harnstoff；N-[(Butylamino)carbonyl]glycine, ethyl ester；ethyl 2-(butylcarbamoylamino)acetate
• CAS: 29346-50-7
• 化学式: C₉H₁₈N₂O₃
• mdl: MFCD06088680
• 分子量: 202.254
• InChiKey: DJDUVDNFQGENPG-UHFFFAOYSA-N

物化性质

• 熔点：
  42-43 °C
• 沸点：
  358.8±25.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-butyl-N'-<(ethoxycarbonyl)methyl>urea 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以97%的产率得到5-丁基海因酸
  参考文献：
  名称：

  7-氧杂双环[2.2.1]庚基羧酸作为血栓烷A2拮抗剂：氮杂欧米茄链类似物。

  摘要：

  新型的双环前列腺素类似物，[1S- [1 alpha，2 alpha（Z），3 alpha，4 alpha]]-7- [3-[[[[[（[Oxoheptyl）amino] acetyl] amino] -methyl]发现-7-氧杂双环[2.2.1]庚-2-基] -5-庚烯酸[-]-7是有效的选择性血栓烷A2（TxA2）受体拮抗剂。与相关系列的ω-链烯丙基醇不同，酰胺7及其同类物在体外（牛冠状动脉）和体内（麻醉的豚鼠）均一致没有直接收缩活性。酰胺7有效抑制（a）花生四烯酸诱导的人血小板丰富血浆的血小板聚集（I50 = 0.18 +/- 0.006 microM），（b）11,9-环氧甲氧基-PGH2诱导的人血小板血小板聚集-血浆（I50 = 0.24 microM），（c）11,9-环氧甲氧基-PGH2诱导的豚鼠气管（Kb = 3.0 +/- 0.3 nM）或大鼠主动脉（Kb = 8.8 +/-

  DOI：

  10.1021/jm00171a021
• 作为产物：
  描述：

  2-氨基乙酰苯胺盐酸盐 以94%的产率得到
  参考文献：
  名称：

  NAKANE, MASARNI;REID, JOYCE A.;HAN, WEN-CHING;DAS, JAGABANDHU;TRUC, VU CH+, J. MED. CHEM., 33,(1990) N, C. 2465-2476

  摘要：

  DOI：

文献信息

• 5,6-epoxy-7-oxabicycloheptane substituted diamide prostaglandin analogs
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04734426A1

  公开（公告）日：1988-03-29

  5,6-Epoxy-7-oxabicycloheptane substituted diamide prostaglandin analogs are provided having the structural formula ##STR1## wherein A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt or ##STR2## q is 1 to 12; and R.sup.1 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, ##STR3## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  提供了结构式为##STR1##的取代二酰胺前列腺素类似物，其中A为--CH.dbd.CH--或--CH.sub.2--CH.sub.2--; n为1到5; R为CO.sub.2H，CO.sub.2烷基，CO.sub.2碱金属，CO.sub.2多羟胺盐或##STR2## q为1到12；而R.sup.1为H，低烷基，低烯基，低炔基，芳基，芳基烷基，低烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基，芳基氨基，芳基烷基氨基，##STR3##（其中n'为0、1或2），烷基氨基烷基，芳基氨基烷基，芳基烷基氨基烷基，烷氧基烷基，芳氧基烷基或芳基烷氧基烷基。这些化合物是心血管药物，例如在治疗血栓性疾病方面有用。
• Bicycloheptane substituted diamide and its congener prostaglandin analogs
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04734424A1

  公开（公告）日：1988-03-29

  Bicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; Q is --CH.dbd.CH--, --CH.sub.2 --, ##STR2## or a single bond; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR3## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S-, aryl-S-, arylalkyl-S-, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  本发明提供了结构式 ##STR1## 的双环庚烷取代酰胺前列腺素类似物，其中m为0至4；A为--CH.dbd.CH--或--CH.sub.2 --CH.sub.2 --；n为1至5；Q为--CH.dbd.CH--、--CH.sub.2 --、##STR2##或单键；R为CO.sub.2 H、CO.sub.2烷基、CO.sub.2碱金属、CO.sub.2多羟基胺盐、--CH.sub.2 OH、##STR3##其中R.sup.4和R.sup.5相同或不同，为H、低碳基、羟基、低烷氧基或芳基，R.sup.4和R.sup.5中至少一个不是羟基和低烷氧基；p为1至4；R.sup.1为H或低碳基；q为1至12；R.sup.2为H或低碳基；R.sup.3为H、低碳基、低烯基、低炔基、芳基、芳基烷基、低烷氧基、芳氧基、芳基烷氧基、氨基、烷基氨基、芳基氨基、芳基烷基氨基、低烷氧基烷基、芳氧基烷基或芳基烷氧基烷基。这些化合物是心血管药物，例如在治疗血栓性疾病方面有用。
• Substituted 2-Thioxoimidazolidin-4-ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates
  作者：Giulio G. Muccioli、Nicola Fazio、Gerhard K. E. Scriba、Wolfgang Poppitz、Fabio Cannata、Jacques H. Poupaert、Johan Wouters、Didier M. Lambert

  DOI：10.1021/jm050977k

  日期：2006.1.1

  The demonstration of the essential role of fatty acid amide hydrolase (FAAH) in hydrolyzing endogenous bioactive fatty acid derivatives has launched the quest for the discovery of inhibitors for this enzyme. Along this line, a set of 58 imidazolidine-2,4-dione and 2-thioxoirnidazolidin-4-one derivatives was evaluated as FAAH inhibitors. Among these compounds, 3-substituted 5,5'-diplietiylimidazolidine-2,4-dione and 3-substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one derivatives were previously described as CB, cannabinoid receptor ligands. In the present study, we synthesized several derivatives exhibiting interesting FAAH inhibitory activity and devoid of affinity for the CB, and CB, cannabinoid receptors. For instance, 3-heptyl-5,5'-diphenylimidazolidine-2,4-dione (14) and 5.5'-diphenyl-3-tetradecyl-2-thioxo-imidazolidin-4-one (46) showed pI(50) values of 5.12 and 5.94, respectively. In conclusion, it appears that even though several 3-substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one and 3-substituted 5.5'-diphenylimidazolidine-2,4-dione derivatives have been previously shown to behave as CB, cannabinoid receptor ligands, appropriate substitutions of these templates can result in FAAH inhibitors devoid of affinity for the cannabinoid receptors.
• Ryczek, J., Polish Journal of Chemistry, 1994, vol. 68, # 12, p. 2599 - 2604
  作者：Ryczek, J.

  DOI：——

  日期：——
• Shvetsova-Shilovskaya,K.D. et al., Journal of general chemistry of the USSR, 1963, vol. 33, # 10, p. 3074 - 3075
  作者：Shvetsova-Shilovskaya,K.D. et al.

  DOI：——

  日期：——